Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 Outubro 2023 - 6:00PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for rare and ultrarare diseases, today reported the grant
of 80,366 restricted stock units of the company’s common stock and
the grant of non-qualified stock options to purchase an aggregate
of 140,469 shares of common stock of the company to Howard Horn,
its newly appointed Chief Financial Officer and Executive Vice
President, Corporate Strategy. The awards were approved by the
compensation committee of the company’s board of directors and
granted under the Ultragenyx Employment Inducement Plan, as
amended, with a grant date of October 9, 2023, as an inducement
material to the new employees entering into employment with
Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the
underlying shares vesting on each anniversary of the grant date,
subject to Mr. Horn being continuously employed by the company as
of such vesting dates. The stock options vest over four years, with
25% of the shares underlying the option vesting on the first
anniversary of the grant date and the remainder vesting with
respect to 1/48th of the shares underlying the options on each
monthly anniversary thereafter, subject to Mr. Horn being
continuously employed by the company as of such vesting dates. The
stock options have a ten-year term and an exercise price of $35.68
per share, equal to the per share closing price of Ultragenyx’s
common stock on October 9, 2023.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel products
to patients for the treatment of serious rare and ultrarare genetic
diseases. The company has built a diverse portfolio of approved
therapies and product candidates aimed at addressing diseases with
high unmet medical need and clear biology for treatment, for which
there are typically no approved therapies treating the underlying
disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx Investors & MediaJoshua Higa(415)
475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024